Almirall joins IL-2 push in autoimmunity with $507m Simcere deal
pharmaphorum
SEPTEMBER 30, 2022
Almirall has licensed an interleukin-2 (IL-2) drug from China’s Simcere Pharma, joining the ranks of companies looking at blocking the cytokine as a way to treat autoimmune diseases. It has also reached a deal with Ablexis to use its antibody development platform in therapeutics. Last year, Merck & Co paid $1.85
Let's personalize your content